GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors

You may be eligible if

• Histologically or cytologically confirmed diagnosis of 1 of the following:
• * Solid tumor malignancy (phase I only)\*
• * Prostate cancer (phase I only)\*
• * Non-small cell lung cancer (phase I and II)\*
• Recurrent, metastatic, locally advanced unresectable, or treatment-refractory disease
• Measurable disease
• * At least 1 unidimensionally measurable lesion at least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
• * Previously irradiated lesions are considered measurable provided they have demonstrated progression before study entry
• * No bone-only disease
• * Must have measurable disease other than bone lesions
• No stage IIIA or IIIB non-small cell lung cancer without a malignant pleural or pericardial effusion that is eligible for first-line radical combined chemotherapy and radiotherapy
• No known progressive or symptomatic brain metastases
• * Asymptomatic brain metastases allowed
• Performance status - ECOG 0-2
• Performance status - Karnofsky 60-100%
• More than 3 months
• WBC at least 3,000/mm\^3
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• No history of coagulopathy
• Bilirubin no greater than 1.5 times upper limit of normal (ULN)
• AST/ALT no greater than 2 times ULN (3.5 times ULN if liver metastases are present)
• INR no greater than 1.3
• APTT no greater than 1.25 times ULN
• Creatinine no greater than 1.5 times ULN
• Creatinine clearance at least 50 mL/min
• No symptomatic congestive heart failure
• No evidence of cardiac dysfunction
• No unstable angina pectoris
• No cardiac arrhythmia
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No active peptic ulcer disease
• No poorly controlled diabetes mellitus
• No pre-existing grade 2 or greater neuropathy
• No ongoing or active infection
• No contraindication to corticosteroids
• No psychiatric illness or social situation that would limit compliance with study requirements
• No prior allergic reaction attributed to compounds of similar chemical or biological composition to study drugs
• No other concurrent uncontrolled illness
• One, and only one, prior chemotherapy regimen for advanced disease (not including adjuvant therapy) allowed
• * Neoadjuvant/adjuvant chemotherapy allowed
• More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas and mitomycin) and recovered
• Prior multiple lines of endocrine therapy for advanced solid tumors allowed
• More than 4 weeks since prior endocrine therapy and recovered
• Concurrent steroids allowed
• See Disease Characteristics
• More than 4 weeks since prior radiotherapy and recovered
• No concurrent radiotherapy to sole site of measurable disease
• Prior surgery allowed
• No concurrent anticoagulant therapy
• * Concurrent low-dose warfarin for central line thrombosis prophylaxis allowed
• No concurrent combination antiretroviral therapy for HIV-positive patients
• No other concurrent investigational or commercial agents or therapies intended to treat the malignancy
• Concurrent bisphosphonates allowed